Class-Wide REMS For Opioids: A Look At The Products Affected
This article was originally published in The Pink Sheet Daily
Executive Summary
Class-Wide REMS For Opioids
You may also be interested in...
FDA Will Require Class-Wide REMS For Opioids; “Massive” Program Compared To Past Efforts
Class-wide REMS will encompass 24 marketed products from 16 different manufacturers; focus on extended-release products.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.